DOP2014000161A - Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales - Google Patents
Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animalesInfo
- Publication number
- DOP2014000161A DOP2014000161A DO2014000161A DO2014000161A DOP2014000161A DO P2014000161 A DOP2014000161 A DO P2014000161A DO 2014000161 A DO2014000161 A DO 2014000161A DO 2014000161 A DO2014000161 A DO 2014000161A DO P2014000161 A DOP2014000161 A DO P2014000161A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- concentration
- volume
- weight
- animals
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Communication Control (AREA)
Abstract
Composición farmacéutica, que comprende cloruro de isometamidium a una concentración entre 1 y 4% (peso/volumen), isopropilidenoglicerol o glicerinformal a una concentración entre 40 y 95% (peso/volumen), un poliol a una concentración entre 0 y 50% (peso/volumen), 15-hidroxiestearato de polietilenglicol a una concentración entre 0,5 y 7% (peso/volumen), en solución junto con excipientes farmacéuticamente aceptables, para el tratamiento de la tripanosomiasis en animales. La composición farmacéutica es una solución inyectable lista para usar y se puede administrar por vía intravenosa, subcutánea o intramuscular en rumiantes, équidos y camélidos. La composición puede comprender además agentes antiparasitarios, como la ivermectina, a una concentración entre 1 y 5 % (peso/volumen) para el tratamiento de la tripanosomiasis y la eliminación de parásitos gastrointestinales y pulmonares en animales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201230092A ES2416004B1 (es) | 2012-01-24 | 2012-01-24 | Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales. |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2014000161A true DOP2014000161A (es) | 2014-08-15 |
Family
ID=46963763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2014000161A DOP2014000161A (es) | 2012-01-24 | 2014-07-14 | Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales |
Country Status (16)
Country | Link |
---|---|
AP (1) | AP2014007798A0 (es) |
AR (1) | AR089037A1 (es) |
BR (1) | BR112014016926A8 (es) |
CL (1) | CL2014001780A1 (es) |
CO (1) | CO6990714A2 (es) |
CR (1) | CR20140278A (es) |
DO (1) | DOP2014000161A (es) |
EC (1) | ECSP14010152A (es) |
ES (1) | ES2416004B1 (es) |
GT (1) | GT201400159A (es) |
MA (1) | MA35868B1 (es) |
MX (1) | MX2014008172A (es) |
NI (1) | NI201400075A (es) |
PE (1) | PE20141472A1 (es) |
UY (1) | UY34479A (es) |
WO (1) | WO2013110830A1 (es) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2024008B (en) * | 1978-06-28 | 1983-02-16 | Merck & Co Inc | Compositions for treating trypanosomiasis infections |
GB8805286D0 (en) * | 1988-03-05 | 1988-04-07 | Schering Agrochemicals Ltd | Trypanocides |
US5496830A (en) * | 1994-09-14 | 1996-03-05 | Johns Hopkins University | Inhibition of hemoflagellates by camptothecin compounds |
DE19854143A1 (de) * | 1998-11-24 | 2000-05-25 | Chambord Ltd | Pharmazeutisches Präparat mit trypanozider und blutschizontozider Wirkung |
FR2819188B1 (fr) * | 2001-01-08 | 2003-03-14 | Virbac Sa | Compositions pulverulentes ou granulees hydrosolubles, a base de phenanthridines et leurs utilisations |
AR060926A1 (es) * | 2007-05-14 | 2008-07-23 | Ciriaco Quiroga | Solucion anestesica transparente de propofol, con baja irritacion venosa. |
KR20080102010A (ko) * | 2007-05-17 | 2008-11-24 | 대원제약주식회사 | 프로포폴을 포함하는 주사제용 조성물 및 이의 제조 방법 |
DE102008007381A1 (de) * | 2008-02-01 | 2009-08-13 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg | Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten |
WO2011042565A2 (en) * | 2009-10-09 | 2011-04-14 | Instituut Voor Tropische Geneeskunde | Antiprotozoal activity |
-
2012
- 2012-01-24 ES ES201230092A patent/ES2416004B1/es not_active Expired - Fee Related
- 2012-07-19 WO PCT/ES2012/070550 patent/WO2013110830A1/es active Application Filing
- 2012-07-19 AP AP2014007798A patent/AP2014007798A0/xx unknown
- 2012-07-19 MX MX2014008172A patent/MX2014008172A/es unknown
- 2012-07-19 BR BR112014016926A patent/BR112014016926A8/pt not_active Application Discontinuation
- 2012-07-19 PE PE2014001030A patent/PE20141472A1/es not_active Application Discontinuation
- 2012-11-29 AR ARP120104496A patent/AR089037A1/es unknown
- 2012-11-29 UY UY0001034479A patent/UY34479A/es not_active Application Discontinuation
-
2014
- 2014-06-13 CR CR20140278A patent/CR20140278A/es unknown
- 2014-06-16 CO CO14130085A patent/CO6990714A2/es unknown
- 2014-07-03 CL CL2014001780A patent/CL2014001780A1/es unknown
- 2014-07-14 NI NI201400075A patent/NI201400075A/es unknown
- 2014-07-14 DO DO2014000161A patent/DOP2014000161A/es unknown
- 2014-07-15 MA MA37215A patent/MA35868B1/fr unknown
- 2014-07-17 GT GT201400159A patent/GT201400159A/es unknown
- 2014-07-21 EC ECIEPI201410152A patent/ECSP14010152A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AP2014007798A0 (en) | 2014-07-31 |
CO6990714A2 (es) | 2014-07-10 |
NI201400075A (es) | 2015-04-13 |
BR112014016926A2 (pt) | 2017-06-13 |
UY34479A (es) | 2013-07-31 |
MA35868B1 (fr) | 2014-12-01 |
ECSP14010152A (es) | 2015-08-31 |
WO2013110830A1 (es) | 2013-08-01 |
AR089037A1 (es) | 2014-07-23 |
ES2416004B1 (es) | 2014-01-28 |
BR112014016926A8 (pt) | 2017-07-04 |
GT201400159A (es) | 2015-11-19 |
MX2014008172A (es) | 2014-10-06 |
CR20140278A (es) | 2014-12-02 |
CL2014001780A1 (es) | 2014-10-24 |
ES2416004A1 (es) | 2013-07-29 |
PE20141472A1 (es) | 2014-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201700056A (es) | Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico. | |
DOP2017000156A (es) | Derivados de glucagón con estabilidad mejorada | |
PH12015502755A1 (en) | Insulin glargine / lixisenatide fixed ratio formulation | |
DOP2017000293A (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
GT201700124A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
CL2017000664A1 (es) | Micropartículas inyectables para la liberación hiper-localizada de agentes terapéuticos | |
BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
AR091233A1 (es) | Composicion farmaceutica que comprende abediterol | |
AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
UY31790A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona | |
DOP2014000161A (es) | Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales | |
CL2016000542A1 (es) | Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis. | |
CL2018000646A1 (es) | Composición farmacéutica inyectable de dosis única y liberación prolongada que comprende nanopartículas poliméricas compuestas por ácido poli-láctico unido a poli-etilenglicol (mpeg-plla), cargadas con probenicid como fármaco que inhibe el canal de panexina-1, útil para tratar o prevenir dolor crónico, en animales o humanos (divisional 3772-15) | |
IN2013MU02585A (es) | ||
EA201690070A1 (ru) | Применение аргинина и/или цитруллина для лечения и/или профилактики остеоартроза | |
AR095149A1 (es) | Medicamento que comprende fenilefrina y paracetamol | |
AR102978A1 (es) | Formulación de relación fija de insulina glargina / lixisenatida | |
IN2013MU02587A (es) | ||
AR078798A1 (es) | Uso de celivarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de celivarona | |
AR091633A1 (es) | Solucion inyectable de acetaminofen para su administracion por via espinal | |
DOP2012000097A (es) | Dispositivo multidosificador para administrar una dosis a paciente | |
IN2013MU02586A (es) |